

Changes in nonalcoholic fatty liver disease spectrum and metabolic markers in people living with HIV after switching to a raltegravir-based regimen

<u>Mohamed Shengir(1)</u>, Wesal Elgretli(2), Bertrand Lebouche(3), Sahar Saeed(4), Agnihotram V. Ramanakumar(5), Andreas Giannakis(3), Alexandra De Pokomandy(3), Joseph Cox(3), Cecilia Costiniuk(3), Jean-Pierre Routy(3), Marina Klein(3), Giada Sebastiani(1,3)

(1)Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada. (2)Department of Medicine, Faculty of Medicine, University of Tripoli, Tripoli, Libya. (3)Chronic Viral Illness Service, McGill University Health Centre, Montreal, Quebec, Canada. (4)Institute for Public Health, Washington University, St. Louis, Missouri, USA. (5)Research Institute, McGill University Health Centre, Montreal, Quebec, Canada.



VIRTUAL April 27 to 29, 2022 #CAHR2022



VIRTUEL 27 au 29 avril 2022 #ACRV2022

www.cahr-acrv.ca



Nonalcoholic fatty liver disease (NAFLD) is a major comorbidity among people living with HIV (PLWH)(1). In such population, NAFLD is associated with metabolic disorders and exposure to certain antiretroviral therapies (ART)(2). The aggressive nature of hepatic steatosis (HS) in HIV patients, mandates exploring less steatogenic antiretroviral options. The effect of ART, particularly integrase inhibitors (INIs), in such context is not fully investigated.

We aimed to evaluate the impact of switching to raltegravir (RAL)-based regimen compared to continuing other ART regimens not containing INIs on NAFLD spectrum, body mass index (BMI), and lipids among HIV mono-infected patients with HS.

- methods used to measure outcomes:
- measurement (LSM).

Background

Objective

Methods

• This is a phase IV, open-label RCT (ClinicalTrials.gov: NCT02210715). Figure 1. (study design)

1. NAFLD spectrum; HS by controlled attenuation parameter (CAP), nonalcoholic steatohepatitis (NASH) by cytokeratin 18 (ck-18), and fibrosis through transient elastography (TE) measuring liver stiffness

2. Lipids & body mass index (BMI); using serum lipids and anthropometrics measurements. • Changes in outcomes over time were represented as standardized mean differences (SMD). Figure 1. Experimental design.


Hepatitis coinfection

Switch arm (RAL 400mg BID)

BMI


kg/m2

CAP



• Suppressed HIV viral load • Hepatic steatosis (HS): defined as CAP) $\geq 238 \text{ dB/m}$

Lipids Lipid profile




End of follow-up (24 months)

Tables Deceline characteristics by anital and control

Table 1. Baseline characteristics by switch and control arms.				Table 2. Fixed-effect line		-		
Variables			– p-value	counterpart using noninvo attenuation parameter; L	•			
	Control (n=15)	Switch (n=16)		—			lent; CR-18=Cy	lokeralin
Age (y)	49.54 (10)	51.07 (8.6)	0.4504	APRI=AST-to-Platelet Ra	110 Inaex; FIB-4=J	10rosis-4J.		
Age at HIV diagnosis (y) Age at new data (y)	52.6 (9)	49.36 (8.4)	0.5228 0.7553 Variables	Univariate model		Multivariate model*		
	53.7 (9.5)	54.1 (8.9)		variables	coefficient	p-value	coefficient	p-value
Male, n (<u>%)*</u>	9 (60)	14 (87.5)	0.0801**	Δ CAP (24 months – baseli	ne)			
Diabetes mellitus, n (<u>%)*</u>	1 (6.7)	1 (6.7)	1	Control group	-0.349	0.6147	-0.641	0.4013
Hypertension, n (<u>%)*</u>	2 (13.3)	5 (31.3)	0.3898	Switch group	-0.729	0.3189	-0.450	0.5547
HIV duration at enrollment (y)	11.7 (4.8)	13.1 (6.8)	0.8365	Difference in slope		0.7110		0.8853
CD4 count (cell/mL)	630.3 (205.6)	540.4 (212.8)	0.3889	ΔLSM				
CD8 count (cell/mL)	645.2 (255.5)	672.4 (209.8)	0.7583	Control group	0.117	0.8263	0.063	0.0306
BMI (kg/m²)	27.7 (5.1)	26.8 (4.6)	0.8433	Switch group	-0.050	0.1376	-0.050	0.1376
Glucose (mmol/L)	5 (1)	5.5 (0.8)	0.2174	Difference in slope		0.7279		0.8853
Platelet count (x10 [°] /L)	203 (44.5)	248.1 (63.1)	0.0965	Δ CK-18	0.070	0 (5 0 (4 0 4 0	- 4054
Creatinine (mg/dL)	79.1 (17)	91.1 (52.4)	0.9509	Control group	-0.379	0.6506	-1.242	0.1254
Triglycerides (mmol/L)	1.5 (1)	1.7 (0.9)	0.4624	Switch group	-2.394	0.0450	-2.407	0.0649
T. cholesterol (mmol/L)	4.4 (1)	4.7 (0.9)	0.5623	Difference in slope A APRI		0.1995		0.4500
ALT (U/L)	19.6 (12.3)	29.2 (11.1)	0.0148**	Control group	0.002	0.3718	0.0003	0.8792
AST (U/L)	17.6 (2.8)	34.2 (23.6)	<0.0001**	Switch group	0.0002	0.8377	0.001	0.3418
CAP (dB/m)	261.6 (34.7)	263.5 (34)	0.8029	Difference in slope	0.0000	0.5362	0.001	0.8486
LSM (kPa)	5.09 (2.2)	6.31 (4.4)	0.5795	ΔFIB-4		0.002		
CK-18 (U/L)	68.1 (49.9)	132.2 (122.9)	0.0690	Control group	-0.232	0.2551	-0.276	0.2563
APRI score	0.2 (0.1)	0.3 (0.2)	0.0131**	Switch group	0.0003	0.8377	-0.221	0.3184
FIB-4 score	13 (38.8)	15.6 (47.6)	0.8180	Difference in slope		0.9823		0.9735

Results

Figure 2. Changes in HS, NASH, and fibrosis between baseline and end of follow up (24 months).



This study indicated that switching to RAL improves AST. There were changes in HS, NASH, and liver fibrosis. However, these findings were lacking power. Larger interventional studies are needed to confirm or refute such findings.

Acknowledgment:

Mohamed Shengir has received PhD fellowship from the Canadian Network on Hepatitis C (CanHepC). CanHepC is funded by a joint initiative of the Canadian Institutes of Health Research (NPC-178912) and the Public Health Agency of Canada.

References:

1. Calza L, Colangeli V, Borderi M, Coladonato S, Tazza B, Fornaro G, et al. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. Infect Dis (Lond). 2019;51(8):593-601. 2. Hanttu A, Vuoti S, Kivelä P, Arkkila P, Lundbom N, Hakkarainen A, et al. Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir. AIDS Patient Care STDS. 2021;35(9):335-41.

Conclusions



